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Abstract: 
The hypothesis that the S allele of the 5-HTTLPR serotonin transporter promoter region is associated 
with increased risk of depression, but only in individuals exposed to stressful situations, has generated 
much interest, research, and controversy since first proposed in 2003. Multiple meta-analyses 
combining results from heterogeneous analyses have not settled the issue. To determine the 
magnitude of the interaction and the conditions under which it might be observed, we performed new 
analyses on 31 datasets containing 38 802 European-ancestry subjects genotyped for 5-HTTLPR and 
assessed for depression and childhood maltreatment or other stressful life events, and meta-analyzed 
the results. Analyses targeted two stressors (narrow, broad) and two depression outcomes (current, 
lifetime). All groups that published on this topic prior to the initiation of our study and met the 
assessment and sample size criteria were invited to participate. Additional groups, identified by 
consortium members or self-identified in response to our protocol (published prior to the start of 
analysis1) with qualifying unpublished data were also invited to participate. A uniform data analysis 
script implementing the protocol was executed by each of the consortium members. Our findings do not 
support the interaction hypothesis. We found no subgroups or variable definitions for which an 
interaction between stress and 5-HTTLPR genotype was statistically significant. In contrast, our 
findings for the main effects of life stressors (strong risk factor) and 5-HTTLPR genotype (no impact on 
risk) are strikingly consistent across our contributing studies, the original study reporting the interaction, 
and subsequent meta-analyses. Our conclusion is that if an interaction exists in which the S allele of 5-
HTTLPR increases risk of depression only in stressed individuals, then it is not broadly generalizable, 
but must be of modest effect size and only observable in limited situations.  
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INTRODUCTION     
Depression negatively impacts health more than any other chronic disease2 and is a leading cause of 
total disease burden worldwide.3 Both genetic and environmental factors influence depression;4 
research on the etiology of depression suggests substantial heritability of 40-50%.4-9 Only recently have 
genome-wide association studies (GWAS) begun to identify and replicate specific loci associated with 
depression.10-12 The findings from these studies suggest that (1) the effects of individual single 
nucleotide polymorphisms (SNPs) on major depressive disorder (MDD) are small in magnitude 
(requiring large sample sizes to detect), and (2) candidate genes generally do not show evidence of 
association in either GWAS or subsequent large-scale meta-analyses.13 Gene-environment interactions 
(GxE) (e.g., genetic variants whose influence on depression risk is only seen under specific 
environmental exposures) are one mechanism that may contribute to the complexity of identifying 
genetic associations with depression.14, 15  
A high profile report of a GxE effect on the development of depression involves an interaction between 
stressful life events and a functional, repeat length polymorphism (5-HTTLPR) in the promoter region of 
the serotonin transporter gene (SLC6A4) on chromosome 17.16 SLC6A4 encodes an integral 
membrane protein that transports the neurotransmitter serotonin from synaptic spaces into presynaptic 
neurons. The short (S) allele of 5-HTTLPR is associated with less transcription of the serotonin 
transporter compared to the long (L) allele.17, 18 The report found that carriers of either one or two 
copies of the S allele of 5-HTTLPR were more likely to develop major depressive disorder, increased 
depressive symptoms, and suicidality in response to childhood maltreatment or other stressful life 
events than were individuals homozygous for the L allele. Furthermore, there was evidence of a dose-
response relationship, with risk of depression higher amongst those with two copies of the S allele 
compared to individuals with only one copy in the presence of stress. This GxE interaction report has 
had considerable influence on the field; it has been cited over 4000 times and over one hundred 
publications have investigated the combined impact of 5-HTTLPR variation and stress on risk for 
depression.  
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However, controversy over the robustness of this GxE interaction continues. Although it is likely that 
GxE interactions play an important role in disease, gene-by-environment studies are challenged by the 
fact that statistical power to detect interactions is typically less than for main effects.19 Furthermore, 
many candidate gene main-effect association reports appear to be false positives.20, 21 As Duncan and 
Keller22 illustrate, this indicates a need for caution regarding similar gene-by-environment hypotheses. 
Several meta-analyses have examined the 5-HTTLPR-by-stress hypothesis, some providing support for 
the interaction and others finding no evidence for it,23-26 with various reasons proposed for the 
differences.22, 25, 27-29 Munafò et al.24 performed a literature-based meta-analysis, finding that only 5 of 
the previously published studies (N = 2 999) used phenotypes and statistical models suitably 
comparable to the original study to be included in the meta-analysis. This meta-analysis did not support 
replication of the original finding. Risch et al.23 obtained individual level data from 10 previously 
published studies (N= 14 250) that met inclusion criteria and analyzed the data using a common model 
based on number of stressful life events. This re-analysis found no evidence for either a main effect or 
interaction effect of 5-HTTLPR on depression. Karg et al.25 (56 studies, N= 40 749) and Sharpley et 
al.26 (81 studies, N= 54 996) both performed literature-based meta-analyses and reported strong 
evidence for the interaction. Karg et al. and Sharpley et al. criticized the previous analyses of Munafò et 
al. and Risch et al. for being too restrictive in their inclusion of studies. The approaches of Karg et al. 
and Sharpley et al., in turn, have been criticized for combining p-values too broadly by allowing studies 
with an opposite direction of effect to supply supportive evidence, by including results from studies with 
incompatible statistical and genetic models, and by including outcomes other than depression.22 One 
key issue contributing to disputes over the appropriateness of the prior reports and meta-analyses is 
the heterogeneity of the studies.22 Heterogeneity pervades many key factors in the prior analyses, 
including measurements of depression and stress, genetic ancestry, and statistical models.  
The primary objective of the current study was to increase understanding of the role 5-HTTLPR might 
play as a moderator of the response to stress as it impacts depression. To address the complexities of 
this topic, we performed a collaborative meta-analysis of data available from the participating studies, 
both published and unpublished, using consistent de novo analyses and variables determined a priori 
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as described in the pre-registered protocol.1 Our collaborative meta-analysis strategy, wherein the 
consortium worked to harmonize phenotypes across studies, to prioritize specific analyses a priori, and 
to apply identical de novo statistical analyses across all participating studies, provided a balance 
between maximizing sample size while minimizing heterogeneity. With this approach and the large 
number of contributing samples, we are well positioned to clarify the relationship between 5-HTTLPR, 
stress, and depression. 
 
METHODS 
Coordinated meta-analysis process 
I. Recruitment of studies 
Our goal was to include data from as many pertinent studies as possible. However, analyses based on 
a small number of samples can be statistically unstable, a problem that is exacerbated in models 
involving multiple covariates and an interaction term. For these reasons, we required participating 
studies to have genotyped at least 300 individuals for 5-HTTLPR and to have assessed depression and 
stress for inclusion. Our recruitment started with groups that had previously published on this topic who 
met our inclusion criteria. Additional groups, identified through referral by existing consortium members 
and self-referral based on the publication of our protocol, that had not published on this topic, but which 
satisfied the inclusion criteria, were also invited to participate. Supplemental Table S1 shows the 
datasets contributing to this meta-analysis and how they relate to the Risch meta-analysis23 based on 
primary data and the three literature-based meta-analyses of Munafò, Karg, and Sharpley.24-26  The 
studies contributing to each analysis varied, with no study contributing results for every analysis. Here 
we cite the foundational papers for the published studies that contributed results to the project.30-58 
II. Development of the protocol 
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The consortium developed an analysis protocol that focused on data harmonization and analysis 
prioritization. The decision was made to analyze childhood maltreatment as a source of stress 
separately from other sources of life stress because childhood maltreatment was assumed to precede 
the initial onset of depression and to have a significant life-long impact.59-61 Life stressors other than 
childhood maltreatment include such things as physical or sexual assault, experience of life-threatening 
illness, loss of employment, loss of a spouse, or military conscription. When possible, analyses of other 
life stressors included information on the timing of both the stressful events and the depression 
assessment. For both childhood maltreatment and broadly defined stress (defined as experiencing 
either childhood maltreatment or other life stress), we examined histories of both lifetime depression 
and current depression (at the time of assessment). In addition to stress exposure and genotype, sex 
and age were used as covariates in our analysis models. Subjects assessed between the ages of 21 
and 30 were of particular interest because of the possibility that the effect might be strongest at these 
ages, which is a similar age range to the individuals in the original report.16  
All analyses were stratified by genetic ancestry. An outline of the primary analyses can be found in 
Supplemental Table S2 and more detailed descriptions of the planned analyses are provided in our 
published protocol.1 All code and documents relevant for running the analyses and meta-analysis are 
available in the public repository at https://github.com/achorton/SD_5HTTLPR. 
III. Analysis script 
The coordinating center at Washington University in St. Louis developed data coding instructions 
(Supplemental Table S3) based on the protocol and wrote an analysis script in R.62 Each participating 
group reformatted their data for the analysis and executed the analysis script locally on their own data. 
Results from these analyses, including coefficients and standard errors for the primary and secondary 
analyses as well as demographic information on the data set, were sent to the coordinating center for 
meta-analysis.  
IV. Quality control assessments  
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Data coding: To ensure high quality data, the analysis team at Washington University examined the 
submitted results for unusual values (e.g., unexpected allele frequencies, sex ratios, stress exposure 
rates, rates of depression diagnoses, missing values). When unusual values were found, the team 
worked with the data providers to ensure that the final results accurately reflected their data.  
Poorly fitted models: For results from a study to be included in a particular meta-analysis, we required a 
minimum of 50 individuals to be phenotyped for all variables in the model and that the resulting |  | < 
10 (corresponding to odds ratios (OR) between 1/20 000 and 20 000). Of the results that satisfied both 
the minimum sample size and restriction on , all of the OR for the interaction terms were within the 
more reasonable range of 1/20 to 20. 
V. Meta-analysis  
Meta-analyses of both the primary and secondary models were performed using the R packages 
rmeta63 and metafor,64 and SAS.65 Because of the great variability of the data sources, all meta-analysis 
results are based on random effects models even though there was little statistical evidence of 
heterogeneity (see Supplemental Table S4).  
VI. Models Analyzed 
In keeping with the original report,16 we tested the following main hypothesis:  
The risk of depression displays an interaction between 5-HTTLPR genotype (LL, LS, SS) and exposure 
to stress: namely, the 5-HTTLPR genotype shows no association to depression in individuals not 
exposed to stress, but shows a dose response effect (increased risk for more copies of the S allele) in 
individuals exposed to stress. Our primary genetic coding was additive in the number of copies of the S 
allele. Our template for analysis is in the form  
𝐷𝑒𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 = 𝑎𝑔𝑒 +  𝑠𝑒𝑥 + 𝑠𝑡𝑟𝑒𝑠𝑠 + 𝑔𝑒𝑛𝑒 + 𝑔𝑒𝑛𝑒 × 𝑠𝑡𝑟𝑒𝑠𝑠 
That is, for a dichotomous depression diagnosis,  
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𝑙𝑜𝑔𝑖𝑡(𝐷) =  𝛽0 + 𝛽1𝑎𝑔𝑒 + 𝛽2𝑠𝑒𝑥 + 𝛽3𝑠𝑡𝑟𝑒𝑠𝑠 + 𝛽4𝑔𝑒𝑛𝑒 + 𝛽5(𝑔𝑒𝑛𝑒 × 𝑠𝑡𝑟𝑒𝑠𝑠). 
Support for the hypothesis that S alleles are associated with an increased risk for depression in stress-
exposed individuals, but not in individuals who are unexposed to stress, would be reflected by an OR > 
1 for the gene x stress interaction term. We examined this main hypothesis in multiple settings in an 
attempt to determine a range of conditions under which the effect might be found. We examined two 
types of stress (childhood maltreatment, other life stress), two categories of depression (depression 
during lifetime, current depression), and two age ranges (all ages, young adults between the ages of 21 
and 30).  
Additional secondary hypotheses (e.g., whether there is a main effect of 5-HTTLPR variation on 
depression, whether the effect is observed when using a dominant model (LL vs SL or SS), whether the 
effect would be observed more strongly in a single sex) were also examined to improve our 
understanding of this complex topic.  
Our broadest analyses incorporated information from studies that could not evaluate the full model 
(e.g., a study with only female subjects, a study with only stress-exposed subjects). These analyses 
performed logistic regression on pooled genotype counts with contributing study coded as a class 
variable in the model.  
We used the results for the sex and stress terms as positive controls because females and stress-
exposed individuals are known to be at increased risk for depression. 
RESULTS 
Our participating groups contributed a total of 43 165 total subjects genotyped for 5-HTTLPR and 
assessed for depression and childhood maltreatment and/or other stressful life events. Of these,        
40 693 (94.3%) were of European ancestry, and after harmonization 38 802 subjects contributed to at 
least one analysis. The non-European samples were distributed across five strata (African, African-
European Admixed, Asian, Pacific Islander, and Hispanic) and were not meta-analyzed due to small 
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sample size. Supplemental Table S5 provides key demographic information about the data included in 
the meta-analyses (e.g., N, S allele frequency, frequencies of the key phenotypes). For each of the 
datasets in Table S5, Table S6 lists whether the study design was cross-sectional or longitudinal, the 
criteria used to diagnose depression, and the assessments used to determine childhood maltreatment 
and other stressful life events. Table S7 provides information about additional datasets for which the 
script was run, but whose results could not be included in any of the primary or secondary analyses. 
Further details about each participating study can be found in Supplemental Table S8. 
Table 1 lists results from analyses across all age groups based on exposure to our two stressors of 
interest and diagnoses of our two depression outcomes. As expected, our two positive control factors, 
sex (OR < 1, indicating that males are at lower risk) and exposure to stress (OR > 1 indicating that 
exposure to stress increases risk), each have strong, consistent, and highly statistically significant 
associations to diagnoses of depression whether the diagnosis was for lifetime depression or current 
depression at the time of assessment. We do not see a main effect association between number of 
copies of the S allele and depression in these analyses, a finding that matches what we would expect 
from prior reports, including the study originally reporting the interaction.16 
Importantly, our meta-analyses do not support the hypothesis that in subjects exposed to stress, 
carrying S alleles for 5-HTTLPR confers a differential and increased risk for either lifetime or current 
depression compared to the impact of carrying S alleles in subjects who were not exposed to stress. In 
fact, when the outcome is current depression, the point estimates for the interaction terms are all in the 
direction opposite of the hypothesis.  
The broad stress analyses examined stress resulting from either childhood maltreatment or other life 
stress. The other life stress exposure was examined in two ways: including only subjects for whom the 
other life stress was documented to have occurred within the five years prior to depression (five years 
prior to assessment if no depression) or including all subjects. The 5-year threshold was chosen to 
match the original study design of Caspi et al. (2003).16 Most of the studies contributing to this set of 
analyses assessed stress over a shorter period, which is more in line with current beliefs about the 
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depressogenic effects of acute stressors experienced in adulthood. 
Forest plots illustrating how the individual studies contribute to the first meta-analysis in Table 1 
(outcome: lifetime depression diagnosis; stress: exposure to childhood maltreatment) are shown in 
Figure 1. The protective effect of being male (Figure 1A) and the risk from stress (Figure 1B) are 
consistent across the individual studies, and correspond to overall p-values of 1.4E-15 and 1.7E-8, 
respectively. The lack of a main effect for the genetic variant in this model is also consistent across the 
studies (Figure 1C). For the interaction terms (childhood maltreatment exposure by number of S alleles) 
(Figure 1D), the point estimates are scattered on both sides of 1, and correspond to an overall p-value 
of 0.49.  
Forest plots for these four key factors (sex, stress, gene, and gene x stress interaction) for the 
remaining analyses summarized in Table 1 are given in Supplemental Figures S1 through S5. Forest 
plots for the interaction terms for the remaining primary and secondary analyses are given in 
Supplemental Figures S6 to S14. 
Our other primary analyses and additional secondary analyses examined questions of the strength, 
robustness, and conditions required to observe the hypothesized interaction. The results presented in 
Table 1 reflect the general consensus of the findings. None of the other primary analyses (results in 
Supplemental Tables S9 through S12) or secondary analyses (results in Supplemental Tables S13 
through S16) resulted in a statistically significant interaction.  
We note that a closely related pair of young adult primary analyses resulted in nominally significant 
interactions (p-value < 0.05 before correction for multiple tests) in the hypothesized direction 
(Supplemental Table S10b). Several factors caution against placing too much confidence in these 
particular results: (i) failure of positive control – the point estimate for exposure to stress is protective for 
depression in these two analyses, counter to our more robust analyses and to what would be expected; 
(ii) they are not supported by closely related analyses – neither the matching analysis based on 
childhood maltreatment only, nor the other young adult analyses are even nominally significant (Tables 
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S10b, S9, and S10a), and the matching analysis with subjects of all ages has the point estimates of 
effect in the opposite direction (Table S11b); (iii) statistical instability – these two analyses only include 
a small number of studies (3 and 4) with a relatively small total sample size (N=583 and N=1142), and 
are primarily driven by results from a single study; and (iv) neither p-value survives correction for the 
number of primary analyses performed. 
Our protocol included secondary analyses to help determine whether analytic refinements might 
strengthen the result and explain why the hypothesized interaction had not heretofore been found 
consistently. To reduce heterogeneity in depression diagnosis, we examined the effect of restricting 
meta-analyses to depression diagnoses based on DSM or ICD criteria (Supplemental Table S13). To 
determine if the interaction might be predominantly expressed in only one sex, we performed meta-
analyses stratified by sex (Supplemental Table S14). We examined alternative coding of the genetic 
effect (dominant, recessive, haplotype) (Supplemental Table S15). Because the question of causation 
depends on temporal order of events, we examined whether the interaction would be stronger if the 
analyses were restricted to data from longitudinal studies that had recorded temporal order 
(Supplemental Table S16). In each case, there is a trade-off between a possible gain in power due to a 
refined phenotype versus a loss in power due to smaller sample size. For these secondary analyses, 
we observed one nominally significant interaction in the opposite direction from the hypothesis 
(Supplemental Table S13, depression diagnosis restricted to DSM or ICD, broad stress, current 
depression, OR = 0.74, p = 0.01), and one nominally significant interaction in the hypothesized direction 
(Supplemental Table S15b), S allele coded as recessive, broad stress, lifetime depression, OR 1.25, p 
= 0.02). In all other analyses, the interaction term was not even nominally significant. 
We evaluated the heterogeneity for the interaction terms in all the previous analyses.  Supplemental 
Table S4 lists the I2 and Q heterogeneity statistics along with the p-value for the Q statistic for all the 
primary and secondary meta-analyses in the subsequent tables, demonstrating that there is generally 
little evidence for heterogeneity in these analyses. In particular, secondary analyses refining the 
diagnostic criteria and the study design did not substantially decrease the heterogeneity. 
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Cumulatively, these primary and secondary results exclude a strong, broadly generalizable interaction 
effect reported in Caspi et al. 2003.16 
 
DISCUSSION 
A hallmark of science is the ability of results to be replicated, a criterion that has been increasingly 
recognized in biological and psychological research.66 The original 2003 report of an interaction 
between 5-HTTLPR genotype and stress exposure on depression16 has remained controversial due to 
inconsistent results from replication efforts. Although some researchers have claimed a replication of 
the hypothesized interaction based on different stressors, different measures of depression, or different 
genetic models,25, 26 other attempts to replicate the finding have been negative.23, 24, 67 The goal of our 
study was to rigorously explore the extent to which the original report could be replicated and 
generalized using a structured collaborative meta-analysis.  
This is the largest study to date to use consistent statistical analyses across all samples to examine the 
hypothesized interaction between 5-HTTLPR genotype and stress exposure affecting major 
depression. As detailed in our protocol,1 our design was based on consistent, de novo analyses chosen 
by a consensus of participating researchers in the field, with inclusion open to all researchers with 
published or unpublished data that met objective minimum participation criteria. The purpose was to 
address multiple issues of concern about previous meta-analyses of the topic: (i) heterogeneity of 
phenotypes, (ii) publication bias from small studies, (iii) heterogeneity of statistical models used to 
produce the input for the meta-analysis, (iv) meta-analysis models that did not take direction of effect 
into account. 
Neither our primary nor our secondary analyses found compelling evidence that the 5-HTTLPR S allele 
increases risk of major depression in individuals exposed to stress. These results are in marked 
contrast to the robust main effect signals seen for the sex and stress exposure, where p-values less 
than 10-60 were seen in our most inclusive primary analyses (Supplemental Table S12). In our effort to 
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determine conditions for which the interaction might be reliably detected, we investigated both 
childhood maltreatment and other life experiences as stressors. Because major depression is a 
recurring and remitting disease subject to recall bias, both current depression and lifetime depression 
were examined. Data from subjects of any age and data limited to young adults were both studied. We 
examined life stress known to precede depression (thereby limiting the sample to studies that 
documented the relative timing of stress and depression) and we investigated whether the 
hypothesized interaction could be more effectively detected using all available data with stress and 
depression assessed. In secondary analyses, we also examined multiple models for the coding of the 
genotype (additive, dominant, recessive, haplotypes) as well as broad and narrow requirements for 
documentation of temporal order of the stress experience and the onset of depression. Despite these 
efforts, we were unable to uncover specific subgroups where the GxE interaction was clearly 
expressed.  
The Caspi group that originally proposed the hypothesis16 raised concerns regarding this meta-analysis 
project; in particular, the decisions to exclude small studies, and to include lifetime depression as an 
outcome for analysis were criticized.68  As noted in our methods, although we required studies to have 
at least 300 participants overall, inclusion in any particular meta-analysis required only 50 of these 
subjects to be genotyped and have the appropriate phenotypes (ancestry, depression outcome, 
covariates). Although Moffitt and Caspi argue that small studies may be meticulously designed and 
have high quality data,68 there is a case to be made that large studies are generally likely to have better 
design quality than small studies.69 In addition, small studies are subject to multiple statistical issues, 
including publication bias (exacerbated for small studies) and the winner’s curse (which makes it likely, 
even if a true effect is detected, that the magnitude will be exaggerated).70 In fact, a 2013 analysis of 
neuroscience publications concluded that small sample size studies were undermining the reliability of 
neuroscience.69  
The concern Moffitt and Caspi raised regarding the inclusion of lifetime depression analyses was the 
difficulty of knowing the relative timing of stress and depression for a lifetime phenotype. Rather than 
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omit these analyses of lifetime depression, as suggested by Moffitt and Caspi, we included analyses 
where timing information was specifically queried as well as analyses where it was not specifically 
queried. We recognize that these data, like all data, have limitations, but nonetheless we find the 
results informative. We note that of all the models examined in our de novo analyses, the only results 
with nominally significant interaction terms in the hypothesized direction were based on lifetime 
depression outcomes. Finally, based on parameter estimates provided in the supplement to their 
seminal paper,16 we can estimate the impact those data would have on both our young adult and all-
age analyses involving depression diagnoses with a quantitative life stress variable. We found that 
none of these analyses were nominally significant even after adding the Caspi et al. (2003) results to 
the meta-analyses. 
The decision by some invited groups not to participate is a limitation of this project. It is becoming 
increasingly clear that large samples are an important tool for determining the role of genetic variation 
in complex phenotypes, such as depression. Combining existing data is an efficient tool for this 
purpose. We expect that in the future data sharing will become the rule rather than the exception. We 
are encouraged by the fact that data sharing is becoming a requirement of funding agencies and a 
requirement for publication by some journals. Although we would have preferred complete participation, 
several factors mitigate the impact that this likely had on our results. First, the phenotypes for several of 
the non-participating groups turned out to be insufficient for inclusion in any of our primary or secondary 
analyses. Second, several of the non-participating groups had exclusively Asian samples, which would 
not have impacted the European ancestry results. Finally, we found that some data reported in the 
large prior meta-analyses as supportive of the interaction were not supportive when all were analyzed 
using the same statistical model for all studies. 
Although our consortium tested many high-priority combinations of factors (see Supplemental Table 
S2), there remain other specific situations that we were unable to evaluate, such as limiting analyses to 
stress over a period shorter than five years, to financial stress,71 to persistent or recurrent depression,29, 
72 or to childhood emotional abuse/neglect only.73 Using data from a diverse set of studies, most 
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designed to address other questions, is also a limitation. However, we note that many of the 
participating studies, despite their diversity, have already been cited in the literature either in support of, 
or against, the hypothesized interaction. 
Our novel contribution is to apply a consistent methodology across the participating studies to query a 
broad range of questions about the hypothesized interaction. Although these studies remain varied in 
their original design, our unified approach to phenotype harmonization and statistical analysis has 
provided a sound and comprehensive exploration of this challenging question. We have addressed and 
excluded the major objections (exclusion of small studies, inclusion of analyses of lifetime depression) 
to our protocol raised by Caspi and Moffitt.  
Our findings do not support the interaction hypothesis. We found no subgroups or variable definitions 
for which an interaction between stress and 5-HTTLPR genotype was statistically significant. In 
contrast, our findings for the main effects of sex (strong risk factor), life stressors (strong risk factor) and 
5-HTTLPR genotype (no impact on risk) are strikingly consistent across the models examined in this 
study. Moreover, these robust main effect results are consistent with the main effect results from the 
Caspi study that originally reported the interaction,16 with the re-examination of the topic using primary 
data by Risch et al.,23 and with prior meta-analyses.23-26 Based on our findings, we conclude that if an 
interaction exists in which the S allele of 5-HTTLPR increases risk of depression only in stressed 
individuals, then it is not a broadly generalizable effect, but must be of modest effect size and only 
observable in limited situations. Our lack of replication coincides with findings of the Christchurch 
Health and Developmental Study,67 a prospective longitudinal birth-cohort, with measures, outcomes, 
and sample (both size and origin on the south island of New Zealand) nearly identical to the original 
report. This lack of evidence for a strong, robust effect should be taken into account before planning 
future research on this topic. 
Supplementary information is available at Molecular Psychiatry’s website.  
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Tables and Figures: 
 
Table 1. Meta-analysis of the impact of a stress-by-5-HTTLPR genotype interaction on depression 
based on new, uniform analyses of harmonized dichotomous phenotypes in subjects of all ages 
Childhood Maltreatment 
Depression Stress Studies Subjects Covariate OR 95% CI p-value 
Lifetime Childhood maltreatment 18 21135 Sex 0.57 (0.50 , 0.66) 1.4E-15 
    Stress 2.16 (1.65 , 2.82) 1.7E-08 
    Gene 1.00 (0.95 , 1.05) 0.95 
    
Gene x stress 1.05 (0.91 , 1.21) 0.49 
Current Childhood maltreatment 13 13956 Sex 0.63 (0.51 , 0.78) 3.5E-05 
      Stress 2.87 (1.87 , 4.41) 1.5E-06 
      Gene 1.00 (0.92 , 1.10) 0.97 
      Gene x stress 0.93 (0.76 , 1.14) 0.50 
Broad Stress 
Depression Stress Studies Subjects Covariate OR 95% CI p-value 
Lifetime Broad stress 19 21938 Sex 0.58 (0.51 , 0.67) 2.8E-15 
 (Other life stress < 5 years prior   Stress 1.82 (1.39 , 2.39) 1.4E-05 
 or childhood maltreatment)   Gene 1.00 (0.95 , 1.06) 0.95 
    Gene x stress 1.06 (0.93 , 1.20) 0.40 
Current Broad stress 14 13835 Sex 0.63 (0.51 , 0.78) 2.4E-05 
 (Other life stress < 5 years prior   Stress 3.19 (2.08 , 4.91) 1.2E-07 
 or childhood maltreatment)   Gene 1.01 (0.90 , 1.12) 0.91 
    Gene x stress 0.92 (0.76 , 1.11) 0.39 
Lifetime Broad stress 21 28252 Sex 0.60 (0.53 , 0.67) 6.5E-17 
 (Other life stress or   Stress 2.00 (1.56 , 2.56) 3.8E-08 
  childhood maltreatment)   Gene 1.00 (0.94 , 1.07) 0.92 
    Gene x stress 1.05 (0.94 , 1.16) 0.38 
Current Broad stress 17 17015 Sex 0.61 (0.49 , 0.75) 5.1E-06 
 (Other life stress or   Stress 2.60 (1.62 , 4.19) 7.8E-05 
  childhood maltreatment)   Gene 1.08 (0.92 , 1.27) 0.35 
    Gene x stress 0.85 (0.68 , 1.07) 0.17 
In this table the childhood maltreatment analyses represent Primary Analysis 2Ai from the hierarchy presented in 
Supplemental Table S2. The broad stress analyses represent Primary Analysis 2Bi from the hierarchy. 
Sex (female = 0; male = 1) 
Stress (not exposed = 0; exposed = 1) 
Gene (additive coding in number of S alleles for 5-HTTLPR (LL = 0; LS=1; SS=2)) 
Broad stress does not require both stressors to be assessed.  
MODEL:  𝑑𝑒𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 = 𝛽0 + 𝛽1(𝑎𝑔𝑒) + 𝛽2(𝑠𝑒𝑥) + 𝛽3(𝑠𝑡𝑟𝑒𝑠𝑠) + 𝛽4(𝑔𝑒𝑛𝑒) + 𝛽5(𝑔𝑒𝑛𝑒 × 𝑠𝑡𝑟𝑒𝑠𝑠) 
Depression variable: depression diagnosis 
Stress variable: dichotomous stress exposure 
Age was not significant in any of the models 
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Figure 1 legend: 
 
Figure 1: Forest plots for the four key factors for the first model listed in Table 1.  
(a) Sex: odds ratio (OR) =0.57, p =1.4e-15;  
(b) stress: OR =2.16, p=1.7e-8;  
(c) gene: OR =1.00, p =0.95;  
(d) gene x Stress: OR=1.05, p=0.49.  
This analysis examined the outcome lifetime depression diagnosis in subjects of all ages based on exposure to 
childhood maltreatment as the stressor. Sex and stress display significant and consistent effects across the studies. 
The main effect of 5-HTTLPR and the interaction between 5-HTTLPR and stress are not significant.  
MODEL:  𝑑𝑒𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 = 𝛽0 + 𝛽1(𝑎𝑔𝑒) + 𝛽2(𝑠𝑒𝑥) + 𝛽3(𝑠𝑡𝑟𝑒𝑠𝑠) +  𝛽4(𝑔𝑒𝑛𝑒) + 𝛽5(𝑔𝑒𝑛𝑒 × 𝑠𝑡𝑟𝑒𝑠𝑠) 
Depression = lifetime depression diagnosis (never depressed = 0; ever depressed = 1) 
Sex (female = 0; male = 1)  
Stress = childhood maltreatment (not exposed = 0; exposed = 1) 
Gene (additive coding in number of S alleles for 5-HTTLPR (LL = 0; LS=1; SS=2)) 
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Sex 
	
Being male consistently and significantly protects from a lifetime diagnosis of depression	
  
 
1a. Sex: Being male consistently and significantly protects from a lifetime diagnosis of depression 
  
Overall summary
0.0 1.0 2.0 3.0 4.0 5.0 6.0
Odds Ratio
TREND
TRAILS
SHIP
NEWMOOD−L2−MAN
NEWMOOD−L1−MAN
NEWMOOD−L1−BP
NESDA−NTR
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GAN12France
ESPRIT
EPIC−Norfolk
DeCC
COGA
CHDS
ALSPAC
3151
1200
1980
231
1211
928
1361
598
745
299
904
277
1301
4023
444
571
702
1209
0.62   (0.51,0.75)
0.40   (0.28,0.57)
0.44   (0.34,0.56)
0.30   (0.16,0.56)
0.44   (0.34,0.57)
0.61   (0.42,0.88)
0.59   (0.41,0.84)
0.90   (0.63,1.27)
1.00   (0.32,3.16)
0.57   (0.29,1.15)
0.86   (0.61,1.23)
0.97   (0.42,2.22)
0.36   (0.27,0.48)
0.60   (0.51,0.70)
0.60   (0.39,0.90)
1.02   (0.69,1.51)
0.58   (0.41,0.81)
0.56   (0.44,0.71)
0.57   (0.50,0.66)
NStudy OR        95% C.I.
21135
1.4e−15Overall P value
All_DD_life_DS_childmal:Sex
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Stress 
Exposure to stress consistently and significantly increases lifetime risk for depression	
  
 
 
1b. Stress: Exposure to stress consistently and significantly increases lifetime risk for depression 
  
Overall summary
0.0 1.0 2.0 3.0 4.0 5.0 6.0
Odds Ratio
TREND
TRAILS
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2.21   (1.46, 3.34)
5.27   (2.67,10.40)
0.70   (0.36, 1.36)
1.70   (0.37, 7.78)
3.20   (1.94, 5.28)
2.27   (1.12, 4.61)
4.23   (1.41,12.66)
3.21   (1.60, 6.44)
1.61   (0.91, 2.85)
3.77   (0.72,19.80)
0.79   (0.47, 1.33)
1.40   (0.18,10.81)
2.23   (1.31, 3.82)
1.75   (1.02, 2.99)
1.51   (0.70, 3.24)
4.50   (2.20, 9.20)
2.40   (1.18, 4.89)
2.53   (1.25, 5.12)
2.16   (1.65, 2.82)
NStudy OR        95% C.I.
21135
1.7e−08Overall P value
All_DD_life_DS_childmal:Stress
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Gene 
	
The S allele (coded additively) is not associated with risk of lifetime depression	
  
 
 
1c. Gene: The S allele (coded additively) is not associated with risk of lifetime depression  
  
Overall summary
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Odds Ratio
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1.32   (0.87,2.00)
1.00   (0.83,1.20)
0.95   (0.74,1.22)
1.15   (0.88,1.51)
0.90   (0.70,1.17)
0.89   (0.65,1.22)
1.18   (0.72,1.96)
0.97   (0.71,1.34)
0.53   (0.27,1.05)
0.91   (0.75,1.11)
1.00   (0.89,1.13)
0.80   (0.59,1.09)
1.05   (0.75,1.47)
1.01   (0.78,1.31)
1.14   (0.96,1.35)
1.00   (0.95,1.05)
NStudy OR        95% C.I.
21135
0.95Overall P value
All_DD_life_DS_childmal:Gene
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Gene x Stress 
 
	
The interaction is not significant and does not suggest a consistent direction of effect across studies 
(Hypothesized direction of effect: OR > 1) 
  
 
 
1d. Gene x Stress: Interaction term is not significant and does not suggest a consistent direction of effect across studies. 
(Hypothesized direction of effect: OR > 1) 
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